Lumiliximab is a chimeric monoclonal antibody serving as an immunosuppressive drug, a primatized macaque/human anti-CD23 antibody for potentially treating allergic conditions. The DrugMonitor™ Anti-Lumiliximab Antibody (VS-1224-YC693) is an anti-drug antibody (ADA) against Lumiliximab. This drug-based antibody is raised in mice immunized with the Lumiliximab. The anti-Lumiliximab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Lumiliximab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-CD23 Recombinant Antibody Lumiliximab(Lumiliximab)Recombinant chimeric (primate/human) antibody expressed in CHO. Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Afuco™ Anti-CD23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-760)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (primate/human) antibody expressed in CHO. It is a monoclonal antibody that targets CD23. It acts as an immunomodulator. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
There are currently no Customer reviews or questions for VS-1224-YC693. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.